English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Zynex
+
Regulatory
Patient Daily
| May 18, 2023
Zynex Announces Proposed $50 Million Offering of Convertible Senior Notes
+
Regulatory
Patient Daily
| May 18, 2023
Zynex Announces Proposed Secondary Public Offering of Common Stock
+
Regulatory
Patient Daily
| May 18, 2023
Zynex Announces Update Regarding Previously Announced Offerings
+
Regulatory
Patient Daily
| May 18, 2023
Zynex Prices Upsized $52.5 Million Convertible Senior Notes Offering
+
Community
Patient Daily
| Apr 24, 2023
Zynex, Inc. to Announce First Quarter 2023 Financial Results
Trending
+
Pharmaceuticals
Patient Daily
| Aug 6, 2026
FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+
Pharmaceuticals
Patient Daily
| Aug 4, 2026
Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+
Regulatory
M. Y. Bailey
| Aug 7, 2026
PhRMA's Zirkelbach: 340B program has changed dramatically with 'little transparency into how patients benefit'
Patient Daily reports
| Aug 10, 2026
SoCal Breathe Free warns persistent sinus symptoms may signal chronic inflammation
